Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) [Research Articles]
This article is highlighted in the In This Issue feature, p. 339
Source: Cancer Discovery - Category: Cancer & Oncology Authors: Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., Doebele, R., Giannetta, L., Cerea, G., Marrapese, G., Schirru, M., Amatu, A., Bencardino, K., Palmeri, L., Sartore-Bianchi, A., Va Tags: Research Articles Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Genetics | Kidney Cancer | Lung Cancer | Melanoma | Oral Cancer | Renal Cell Carcinoma | Skin Cancer | Study